• Zacks Investment Research Lowers Capricor Therapeutics (CAPR) to Sell

    Zacks Investment Research lowered shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a sell rating in a research report released …

    Read More
  • 0 0